PARP1 and leiomyosarcoma: As expected, the rucaparib inhibited basal PARP-1 activity (reducing the amount of PARylated proteins) in all cell lines, and we observed an effect of trabectedin and combination of drugs only in leiomyosarcoma cells (IB136) (Fig. 1).